Ireland
--:--IST
Recruiting Phase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT07353931 · tracked via the Priya Life Science South Korea tracker
Phase
Phase 3
Started
2026-02-09
Last updated
2026-10-08

Condition(s) studied

OsteoarthritisOverweight or Obesity

Investigational drug(s) / intervention(s)

Eloralintide →Placebo

Eloralintide: Administered SC

Placebo: Placebo administered SC

Study summary

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening * Have a stable body weight (less than 5% body weight change) for 90 days prior to screening * Have tried at least once to lose weight through diet but were unsuccessful * Have osteoarthritis of the knee and at least one of the following conditions: * Be over 50 years old * Have morning knee stiffness that lasts about 30 minutes * Have a crackling or grinding sound or feeling in the knee Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Have an active knee infection * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Primary outcome measure(s)

  • Percent Change from Baseline in Body Weight — Baseline, Week 64
    Percent Change from Baseline in Body Weight
  • Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score — Baseline, Week 64
    Change from Baseline in the WOMAC Pain Subscale Score

Trial sites (153)

FacilityCityRegionStatus
AMR Clinical Mobile Alabama Recruiting
Care Access - 801 South Power Road, Mesa Mesa Arizona Recruiting
Elite Pain and Spine Institute - South Crimson Road Mesa Arizona Recruiting
Elite Clinical Studies, LLC Phoenix Arizona Recruiting
Tucson Orthopaedic Institute - North Wyatt Drive Tucson Arizona Recruiting
Ark Clinical Research - Fountain Valley Fountain Valley California Recruiting
Wolverine Clinical Trials Santa Ana California Recruiting
Encompass Clinical Research Spring Valley California Recruiting
Diablo Clinical Research, Inc. Walnut Creek California Recruiting
Skylight Health Research - Colorado Springs Colorado Springs Colorado Recruiting
Westside Center for Clinical Research Jacksonville Florida Recruiting
Care Access - St. Petersburg St. Petersburg Florida Recruiting
Conquest Research Winter Park Florida Recruiting
Orita Clinical Research Decatur Georgia Recruiting
North Georgia Clinical Research Woodstock Georgia Not Yet Recruiting
Medical Research Partners Ammon Idaho Recruiting
Great Lakes Clinical Trials - Ravenswood Chicago Illinois Recruiting
Qualmedica Research, LLC Evansville Indiana Recruiting
AMR Clinical Newton Kansas Recruiting
Monroe Biomedical Research - Louisville Louisville Kentucky Recruiting
Skylight Health Research - Burlington Burlington Massachusetts Recruiting
Care Access - Quincy Quincy Massachusetts Recruiting
Ellipsis Research Group - Brooklyn - 7th Street Brooklyn New York Recruiting
Rochester Clinical Research - Buffalo Buffalo New York Recruiting
NYC Research INC Long Island City New York Recruiting
Rochester Clinical Research, LLC Rochester New York Recruiting
Central States Research Tulsa Oklahoma Recruiting
Keystone Clinical Studies Plymouth Meeting Pennsylvania Recruiting
JCCT - Juno Bellaire Site Bellaire Texas Recruiting
Epic Medical Research - DeSoto DeSoto Texas Recruiting
Valley Institute of Research - Fort Worth Fort Worth Texas Recruiting
Care Access - Houston Houston Texas Recruiting
VIP Trials San Antonio Texas Recruiting
Endeavor Clinical Trials San Antonio Texas Recruiting
Consano Clinical Research, LLC Shavano Park Texas Recruiting
Texas Valley Clinical Research Weslaco Texas Recruiting
AMR Clinical South Jordan Utah Recruiting
Charlottesville Medical Research Charlottesville Virginia Recruiting
Paramount Clinical Research - Data Point Clinical Research Kirkland Washington Recruiting
Centro Privado de Medicina Familiar / Mindout Research Buenos Aires Argentina Not Yet Recruiting

+ 113 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07353931 on ClinicalTrials.gov ↗ ← All trials in South Korea